Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model. - Wikidata - wikimedia - TriplyDB

Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model.

Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model.

http://www.wikidata.org/entity/Q35791258

about

LRP-1: a checkpoint for the extracellular matrix proteolysis TIMP1 promotes multi-walled carbon nanotube-induced lung fibrosis by stimulating fibroblast activation and proliferation Anti-cancer activity of a novel small molecule compound that simultaneously activates p53 and inhibits NF-κB signaling Expression and Subcellular Distribution of GFP-Tagged Human Tetraspanin Proteins in Saccharomyces cerevisiae Targeting pathways downstream of KRAS in lung adenocarcinoma.Design, synthesis, and biological evaluation of novel EF24 and EF31 analogs as potential IκB kinase β inhibitors for the treatment of pancreatic cancer IKK is a therapeutic target in KRAS-Induced lung cancer with disrupted p53 activity.Epidermal p65/NF-κB signalling is essential for skin carcinogenesis NF-κB, an active player in human cancers.TBK1 kinase addiction in lung cancer cells is mediated via autophagy of Tax1bp1/Ndp52 and non-canonical NF-κB signalling.CDA-2, a urinary preparation, inhibits lung cancer development through the suppression of NF-kappaB activation in myeloid cell.A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin A versatile modular vector system for rapid combinatorial mammalian genetics NKX2-1-mediated p53 expression modulates lung adenocarcinoma progression via modulating IKKβ/NF-κB activation.The canonical NF-κB pathway differentially protects normal and human tumor cells from ROS-induced DNA damage TIMP-1 mediates TGF-β-dependent crosstalk between hepatic stellate and cancer cells via FAK signaling.Screening for tumor suppressors: Loss of ephrin receptor A2 cooperates with oncogenic KRas in promoting lung adenocarcinoma.A quinoxaline urea analog uncouples inflammatory and pro-survival functions of IKKβ Targeting NF-κB in glioblastoma: A therapeutic approach Active IKKβ promotes the stability of GLI1 oncogene in diffuse large B-cell lymphoma.Targeting the NF-κB and mTOR pathways with a quinoxaline urea analog that inhibits IKKβ for pancreas cancer therapy.Dioxonaphthoimidazoliums AB1 and YM155 disrupt phosphorylation of p50 in the NF-κB pathway Neutrophil-Derived IL-1β Impairs the Efficacy of NF-κB Inhibitors against Lung Cancer.TIMP-1 and CD82, a promising combined evaluation marker for PDAC.Mouse models for lung cancer Roles of matrix metalloproteinases and their natural inhibitors in prostate cancer progression.Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets.Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.Tissue inhibitor of metalloproteinases-1 induces a pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes.Small GTPase Rab37 targets tissue inhibitor of metalloproteinase 1 for exocytosis and thus suppresses tumour metastasis.Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-κB and mTOR dual-targeting approach.GSK-3α promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical NF-κB.Epithelial NF-κB signaling promotes EGFR-driven lung carcinogenesis via macrophage recruitment.RelA regulates CXCL1/CXCR2-dependent oncogene-induced senescence in murine Kras-driven pancreatic carcinogenesis Opening a new GATAway for treating KRAS-driven lung tumors.RIP4 inhibits STAT3 signaling to sustain lung adenocarcinoma differentiation.Context-Dependent Role of IKKβ in Cancer.IKKα inactivation promotes Kras-initiated lung adenocarcinoma development through disrupting major redox regulatory pathways.Non-canonical IKKs, IKKϵ and TBK1, as novel therapeutic targets in the treatment of non-small cell lung cancer.Tissue inhibitor of metalloproteinase-1 promotes cell proliferation through YAP/TAZ activation in cancer.

P2860

Q21285122-0B61C10C-82BF-4D8A-B052-DE00DB9CC8DA Q27968993-B1EEAD5E-761E-4CBB-9918-06D0CF86E108 Q28483751-DB1CACB4-8A32-4C60-A573-3444F82E229A Q28546836-4BC44504-C2CD-4D89-BCE4-32A42DC07038 Q30597330-8B1A0854-CF73-495D-9A17-2AE04C13039B Q33713919-46C3CD7C-7A49-4190-BB5A-754FF4FA734E Q33776852-E5CA278A-136F-4840-9F58-3F565FA038C0 Q33991488-044E484B-DD66-4FC1-97F9-2CC73713512B Q34138728-EB3C8B23-EACE-41D5-959C-BA398743442B Q34500600-93EE4F5C-9638-4A01-A42E-B2218131E99D Q34533022-929E5783-E9AA-47AB-BA70-BB2551C3590E Q35078290-BE774EAB-47D8-48FE-9A70-D7713E7729CE Q35408740-6295C6DE-B9C9-4908-A59B-6D3EA3E9D0B0 Q35987328-DBFA0073-D55C-4FFB-A4C4-8B8816E7A865 Q36205234-36207AC8-7F48-4456-9482-2F8C939FBAAB Q36262680-7E7C8280-0700-4F36-9045-87135C897B08 Q36331953-66DC3C22-D357-4D98-8DCF-19B26628268C Q36395993-FDEEE7E8-CE7F-497D-BB59-D8EBDE001103 Q36514117-2C031462-25A7-4090-ACD9-EECEE7B937F9 Q36547802-8C18B212-D629-4AA4-BA5B-930D6FE7CBC2 Q36778047-F1C363F8-C03D-4A54-BC25-B82CC2F1F41E Q36998326-E52D5DE4-AFC1-40D3-A466-CFCB0BCBE208 Q37053032-821F60B1-4EFB-4A94-B906-98006B7FE54E Q37701628-E003B988-B726-4979-8CDF-E20E9914ED84 Q38088500-6B08A32E-F625-42F6-8A00-0A8DFA868D79 Q38224605-63F02B23-F378-4E5C-A9C4-DB2A82C1169F Q38622790-08CE1272-4E26-424C-BE87-9718CAA3716C Q38923020-76B746B9-AF35-41D8-96CC-ECB12E61D51A Q38952592-16030241-AF49-4D63-91A8-F3A1D496DB9C Q38960274-00E0210D-975D-4C78-BF3B-4BB8A2CE4EAD Q39107517-67639F89-3EB8-4664-8BCE-F769DA9BE79E Q39172686-D2052D82-B498-4642-ABFF-173986140F3B Q39546462-28BDE127-9C74-4F4B-8819-F70DE0B7AAB4 Q39563697-BE6B30DE-3BE5-4CB4-AEA4-30D1DE99C32E Q40915601-AF23DC38-8434-46A5-B966-C57240F25B30 Q41636930-E3BEFAA3-1119-4183-B787-9EBB3061314D Q47159733-E8ED1142-9744-4FDB-B4A0-37E46777DF97 Q47564540-01921979-414F-499E-9211-D73E4B3A7EC9 Q47681132-45CEF1CC-5BD5-4384-B27D-2BF701CAA242 Q47780433-26339E26-B8B7-4AB0-99EE-E12EC6CE658C

P2860

Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model.

http://www.wikidata.org/entity/Q35791258

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model.

@ast

Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model.

@en

type

label

Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model.

@ast

Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model.

@en

prefLabel

Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model.

@ast

Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model.

@en

P1433

Q35791258-85EE9369-3C80-44BD-901B-59319E6A8654

P1476

Q35791258-3E121391-BEAC-44E2-9979-E8F7C3311E1B

P2093

Q35791258-1AC8043A-14F1-4753-9F8C-A8C9808C88B3

Q35791258-6205848E-5A89-439E-B619-97FDB94E6177

Q35791258-80B1596E-5711-4386-9F27-2E059CFF6B11

Q35791258-92981F37-CE51-4F0F-836B-0951BE75101A

Q35791258-D8777331-6833-4C1C-BB00-98AEDBFB01E2

Q35791258-DDBDB1D0-2E9A-45FC-B6BB-EF875CFEF259

Q35791258-F4BADFE8-80EE-408E-B8C5-638EC19DEBD0

Q35791258-F726B744-2220-4B85-833F-9432A2B09801

P2860

Q35791258-0026C2D8-A760-49D3-AA98-C1256B2B8A2D

Q35791258-10C53583-CCFD-458E-B898-2AFE9D5C3F42

Q35791258-1B10D9BA-6280-4039-ADE6-7F765325FCDF

Q35791258-1EFE06E5-F5E5-4ADC-BF7D-7124A602A351

Q35791258-2BCD5749-D738-40A9-987F-61C11BA9EB73

Q35791258-359A3DE9-0DBD-45BC-919A-8FC354DE0BFE

Q35791258-36EE08DD-AF97-4B68-8918-1F893E3D8C32

Q35791258-395C4004-FE33-40D6-B7F2-91E68B264344

Q35791258-52BF4995-5A9F-4940-9F07-F8A399807473

Q35791258-5D675AF1-F124-4F90-A4CD-347AFAAF7521

P2888

Q35791258-162743AF-0CDC-442B-8183-268F6185398B

P304

Q35791258-4175E02E-4AA4-4640-8529-607C406BFF14

P31

Q35791258-2AF61CDA-2752-4B0D-9310-F9FFB5CE2DA6

P356

Q35791258-29323A29-17E1-4DBD-92BA-C225ED95E2C6

P433

Q35791258-01815B7E-AAB6-4EE3-AFEC-244E47B9849A

P478

Q35791258-C6641A5F-866D-405A-8C9C-5EB7DC641BF8

P577

Q35791258-FEA3CEDA-426C-4B82-99AD-0039BD3B8C4A

P5875

Q35791258-AF4F8120-1333-4433-9634-3883A77D3DFC

P698

Q35791258-E78970BF-098A-4155-8A2E-F67C4543137F

P932

Q35791258-DEADB4FB-849A-4565-8060-8A678F4B8834

P356

P1433

Nature Cell Biology

P1476

Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model.

@en

P2093

Eric Oldfield

http://www.w3.org/2001/XMLSchema#string

Eugene Ke

http://www.w3.org/2001/XMLSchema#string

Inder M Verma

http://www.w3.org/2001/XMLSchema#string

Mathias Leblanc

http://www.w3.org/2001/XMLSchema#string

Narayana Yeddula

http://www.w3.org/2001/XMLSchema#string

Reuben J Shaw

http://www.w3.org/2001/XMLSchema#string

Yifeng Xia

http://www.w3.org/2001/XMLSchema#string

Yonghui Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls

Somatic mutations affect key pathways in lung adenocarcinoma

Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity

Cancer-related inflammation

NF-kappaB regulation in the immune system

Signals from within: the DNA-damage-induced NF-kappaB response

PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes

P2888

P304

257-265

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NCB2428

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221825801

http://www.w3.org/2001/XMLSchema#string

P698

22327365

http://www.w3.org/2001/XMLSchema#string

P932

3290728

http://www.w3.org/2001/XMLSchema#string